 | Up a level |
Meier, FM; Frommer, KW; Dinser, R; Walker, UA; Czirjak, L; Denton, CP; Allanore, Y; Distler, O; Riemekasten, G; Valentini, G; Müller-Ladner, U; Matucci-Cerinic, M; Guiducci, S; Tyndall, A; Lapadula, G; Iannone, F; Becvar, R; Sierakowsky, S; Kowal-Bielecka, O; Cutolo, M; ... (2012). Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Annals of the rheumatic diseases, 71(8), pp. 1355-1360. London: BMJ Publishing Group 10.1136/annrheumdis-2011-200742
Finckh, A; Ciurea, A; Burlhart, L; Möller, B; Walker, UA; Courvoisier, D; Kyburz, D; Dudler, J; Gabay, C (2009). Which Subgroup of Rheumatoid Arthritis Patients Benefits Most From Swichting to Rituximab Versus Alternative Anti-TNF Agenst After Previous Failure To Anit-TNF Agent? Annals of the rheumatic diseases, 69(2), pp. 387-393. London: BMJ Publishing Group 10.1136/ard.2008.105064
